Serum tyrosine associates with increased CSF Aβ42, reduced Aβ deposition, and cognitive improvement in MCI: modulation by confounding factors.

Saved in:
Bibliographic Details
Title: Serum tyrosine associates with increased CSF Aβ42, reduced Aβ deposition, and cognitive improvement in MCI: modulation by confounding factors.
Authors: Dhiaa Younis, Shahad Mohammed (AUTHOR), Shareef, Abdulkareem (AUTHOR), Kumar Bishoyi, Ashok (AUTHOR), Roopashree, R. (AUTHOR), Kashyap, Aditya (AUTHOR), Pramanik, Atreyi (AUTHOR), Ray, Subhashree (AUTHOR), Mavlyanova, Zilola (AUTHOR), Naji Sameer, Hayder (AUTHOR), Yaseen, Ahmed (AUTHOR), H. Athab, Zainab (AUTHOR), Adil, Mohaned (AUTHOR)
Source: International Journal of Neuroscience. Mar2026, Vol. 136 Issue 3, p343-358. 16p.
Subjects: Mild cognitive impairment, Amyloid beta-protein, Cognition disorders, Amyloid plaque, Tyrosine, Cerebrospinal fluid, Cognitive ability
Abstract: Background: Tyrosine, a precursor to dopamine, norepinephrine, and epinephrine, has shown mixed results in cognitive impairment studies, suggesting a complex role in mild cognitive impairment (MCI). This study is the first to explore its relationship with CSF amyloid-beta (Aβ) 42, Aβ accumulation, and cognitive function in MCI (n = 251). Method: Cognitive function was assessed using ADAS-Cog, serum tyrosine by UPLC-MS/MS, Aβ42 by ELISA, and Aβ accumulation via florbetapir PET with SUVr, all validated with quality control. Two analysis models were used: Model 1 (unadjusted) and Model 2 (adjusted for age, gender, education, handedness, and ApoE status). Results: The study found a significant positive link between serum tyrosine levels and CSF Aβ42, with higher tyrosine levels associated with increased Aβ42, independent of demographic and genetic factors. Mediation analysis revealed that in Model 1, higher serum tyrosine was associated with improved cognitive function, potentially through increased CSF Aβ42 levels. However, this association was not present after adjusting for confounders in Model 2. Further investigation of Aβ accumulation in specific brain regions (global, frontal, temporal, and parietal lobes) found that, in Model 1, higher serum tyrosine was linked to reduced Aβ accumulation in the frontal and temporal lobes, wich in turn correlated with better cognitive function. Yet, after adjusting for confounders in Model 2, these effects were no longer significant. Conclusion: Overall, the findings suggest that while serum tyrosine may influence cognitive improvement in MCI through its relationship with CSF Aβ42 and Aβ accumulation, these effects are strongly influenced by demographic and genetic factors. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Neuroscience is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background: Tyrosine, a precursor to dopamine, norepinephrine, and epinephrine, has shown mixed results in cognitive impairment studies, suggesting a complex role in mild cognitive impairment (MCI). This study is the first to explore its relationship with CSF amyloid-beta (Aβ) 42, Aβ accumulation, and cognitive function in MCI (n = 251). Method: Cognitive function was assessed using ADAS-Cog, serum tyrosine by UPLC-MS/MS, Aβ42 by ELISA, and Aβ accumulation via florbetapir PET with SUVr, all validated with quality control. Two analysis models were used: Model 1 (unadjusted) and Model 2 (adjusted for age, gender, education, handedness, and ApoE status). Results: The study found a significant positive link between serum tyrosine levels and CSF Aβ42, with higher tyrosine levels associated with increased Aβ42, independent of demographic and genetic factors. Mediation analysis revealed that in Model 1, higher serum tyrosine was associated with improved cognitive function, potentially through increased CSF Aβ42 levels. However, this association was not present after adjusting for confounders in Model 2. Further investigation of Aβ accumulation in specific brain regions (global, frontal, temporal, and parietal lobes) found that, in Model 1, higher serum tyrosine was linked to reduced Aβ accumulation in the frontal and temporal lobes, wich in turn correlated with better cognitive function. Yet, after adjusting for confounders in Model 2, these effects were no longer significant. Conclusion: Overall, the findings suggest that while serum tyrosine may influence cognitive improvement in MCI through its relationship with CSF Aβ42 and Aβ accumulation, these effects are strongly influenced by demographic and genetic factors. [ABSTRACT FROM AUTHOR]
ISSN:00207454
DOI:10.1080/00207454.2025.2544791